These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18074643)

  • 1. The gender conundrum.
    Fitzpatrick L
    Time; 2007 Nov; 170(21):59. PubMed ID: 18074643
    [No Abstract]   [Full Text] [Related]  

  • 2. Transition memories: experiences of trans adult women with hormone therapy and their beliefs on the usage of hormone blockers to suppress puberty.
    Giovanardi G; Morales P; Mirabella M; Fortunato A; Chianura L; Speranza AM; Lingiardi V
    J Endocrinol Invest; 2019 Oct; 42(10):1231-1240. PubMed ID: 30953318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRH antagonists are safer than agonists: an update of a Cochrane review.
    Al-Inany HG; Youssef MA; Aboulghar M; Broekmans F; Sterrenburg M; Smit J; Abou-Setta AM
    Hum Reprod Update; 2011; 17(4):435. PubMed ID: 21646384
    [No Abstract]   [Full Text] [Related]  

  • 4. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for psychoendocrine studies of puberty.
    Hays SE
    Psychoneuroendocrinology; 1978 Jan; 3(1):1-15. PubMed ID: 417360
    [No Abstract]   [Full Text] [Related]  

  • 6. Gonadotropin-releasing hormone antagonists: impact of IVF practice and potential non-assisted reproductive technology applications.
    Tarlatzis BC; Bili HN
    Curr Opin Obstet Gynecol; 2003 Jun; 15(3):259-64. PubMed ID: 12858116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the use of puberty blockers among transgender children in the United States.
    Lopez CM; Solomon D; Boulware SD; Christison-Lagay ER
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):665-670. PubMed ID: 29715194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the gonadotropin-releasing hormone antagonist cetrorelix on the prevention of chemotherapy-induced ovarian damage in women with hematological malignancy.
    Digeni A; Symeonidis A; Georgopoulos NA
    Int J Gynaecol Obstet; 2012 Jul; 118(1):73-4. PubMed ID: 22503495
    [No Abstract]   [Full Text] [Related]  

  • 9. The endocrinologist's office-puberty suppression: saving children from a natural disaster?
    Sadjadi S
    J Med Humanit; 2013 Jun; 34(2):255-60. PubMed ID: 23494333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer: making the switch from LHRH antagonist to LHRH agonist.
    Moul JW
    Nat Rev Urol; 2012 Jan; 9(3):125-6. PubMed ID: 22289702
    [No Abstract]   [Full Text] [Related]  

  • 11. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy.
    Msaouel P; Diamanti E; Tzanela M; Koutsilieris M
    Expert Opin Emerg Drugs; 2007 May; 12(2):285-99. PubMed ID: 17604502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GnRH antagonist].
    Yano T; Taketani Y
    Nihon Rinsho; 2001 Jan; 59 Suppl 1():133-8. PubMed ID: 11235152
    [No Abstract]   [Full Text] [Related]  

  • 13. Current and Emerging Medical Treatments for Uterine Fibroids.
    Chwalisz K; Taylor H
    Semin Reprod Med; 2017 Nov; 35(6):510-522. PubMed ID: 29100239
    [No Abstract]   [Full Text] [Related]  

  • 14. GnRH antagonists.
    Chabbert-Buffet N; Olivennes F; Bouchard P
    Clin Obstet Gynecol; 2003 Jun; 46(2):254-64. PubMed ID: 12808379
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer: a review.
    Elter K; Nelson LR
    Obstet Gynecol Surv; 2001 Sep; 56(9):576-88. PubMed ID: 11524623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [GnRH antagonists--a new therapy option for advanced prostate cancer].
    Wolff JM
    Aktuelle Urol; 2009 May; 40(3):159-63. PubMed ID: 19399720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists.
    Schultze-Mosgau A; Griesinger G; Altgassen C; von Otte S; Hornung D; Diedrich K
    Expert Opin Investig Drugs; 2005 Sep; 14(9):1085-97. PubMed ID: 16144493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications for GnRH antagonists.
    Blithe DL
    Trends Endocrinol Metab; 2001 Aug; 12(6):238-40. PubMed ID: 11476072
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects on behavior of modulation of gonadal function in men with gonadotropin-releasing hormone antagonists.
    Loosen PT; Purdon SE; Pavlou SN
    Am J Psychiatry; 1994 Feb; 151(2):271-3. PubMed ID: 8296903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?
    Fauser BC; Devroey P
    Fertil Steril; 2005 Jun; 83(6):1607-11. PubMed ID: 15950626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.